DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

• Главные авторы: Forike K. Martens (Автор), Daan W. Huntjens (Автор), Tessel Rigter (Автор), Meike Bartels (Автор), Pierre M. Bet (Автор), Martina C. Cornel (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2020-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

IntroductionThe fluoropyrimidines (FP) (5-Fluorouracil, capecitabine, and tegafur) are commonly used anti-cancer drugs, but lead to moderate to severe toxicity in about 10-40% of patients. DPD testing [either the enzyme activity of dihydropyrimidine dehydrogenase (DPD) or the DPYD genotype] identifi...